Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Globe Newswire•14/10/2026•09:30 ET
0
Key Highlights
- ➤GOBLET Cohort 5 enrollment completed; final PanCAN grant payment expected this quarter
- ➤Cohort 4 final results expected Q4 2026; Cohort 5 initial results expected first half 2027
- ➤Cohort 4 median overall survival exceeds Oncolytics’ expectations
- ➤Oncolytics will use clinical data to guide pelareorep checkpoint-inhibitor strategy
- ➤Each fully enrolled cohort met its pre-specified efficacy success criteria
Expert Statements
Jared Kelly, Chief Executive Officer of Oncolytics
“We are incredibly grateful to PanCAN for its support of GOBLET Cohort 5 and, more broadly, for the extraordinary work the organization does every day on behalf of patients and families affected by pancreatic cancer.”
Jared Kelly, Chief Executive Officer of Oncolytics
“PanCAN has played an important role in advancing pancreatic cancer research by bringing together patients, researchers, clinicians, and industry around the shared goal of developing better treatments for this devastating disease.”
Jared Kelly, Chief Executive Officer of Oncolytics
“We are proud to have worked with PanCAN through GOBLET and deeply appreciate the organization’s support as we complete this phase of the study and continue following patients in our anal and pancreatic cancer cohorts.”
Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics
“The efficacy data from Cohort 5, including overall survival and duration of response, continue to mature, and we will provide an update to investors and stakeholders as soon as possible.”
Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics
“In parallel, we continue to monitor patients in Cohort 4 and are happy to report that median overall survival exceeds our expectations.”
Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics
“The full data set is still being processed, and we anticipate sharing more details before the end of the year.”
Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5
Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the first half of 2027
Get started
Create a free account to read the full story.